MX2023003021A - Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. - Google Patents

Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.

Info

Publication number
MX2023003021A
MX2023003021A MX2023003021A MX2023003021A MX2023003021A MX 2023003021 A MX2023003021 A MX 2023003021A MX 2023003021 A MX2023003021 A MX 2023003021A MX 2023003021 A MX2023003021 A MX 2023003021A MX 2023003021 A MX2023003021 A MX 2023003021A
Authority
MX
Mexico
Prior art keywords
cedna vectors
fviii protein
expression
methods
viral dna
Prior art date
Application number
MX2023003021A
Other languages
English (en)
Inventor
Phillip Samayoa
Douglas Anthony Kerr
Debra Klatte
Nathaniel Silver
Luke S Hamm
Russell Monds
Jessica Lynn Keenan
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MX2023003021A publication Critical patent/MX2023003021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La solicitud describe vectores de ADNec que tienen una estructura lineal y continua para la administración y expresión de un transgén. Los vectores de ADNec comprenden un casete de expresión flanqueado por dos secuencias de ITR, donde el casete de expresión codifica un transgén que codifica una proteína FVIII. Algunos vectores adicionales de ADNec comprenden además elementos reguladores cis, que incluyen interruptores reguladores. En la presente descripción se proporcionan además métodos y líneas celulares para una expresión génica confiable de la proteína FVIII in vitro, ex vivo e in vivo usando los vectores de ADNec. En la presente descripción se proporcionan métodos y composiciones que comprenden vectores de ADNec útiles para la expresión de la proteína FVIII en una célula, tejido o sujeto, y métodos de tratamiento de enfermedades con dichos vectores de ADNec que expresan la proteína FVIII. Tal proteína FVIII se puede expresar para tratar enfermedades, p. ej., hemofilia A.
MX2023003021A 2020-09-16 2021-09-16 Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. MX2023003021A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079349P 2020-09-16 2020-09-16
US202063132838P 2020-12-31 2020-12-31
PCT/US2021/050715 WO2022061014A1 (en) 2020-09-16 2021-09-16 Non-viral dna vectors and uses thereof for expressing fviii therapeutics

Publications (1)

Publication Number Publication Date
MX2023003021A true MX2023003021A (es) 2023-05-24

Family

ID=80776405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003021A MX2023003021A (es) 2020-09-16 2021-09-16 Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.

Country Status (9)

Country Link
US (1) US20230383311A1 (es)
EP (1) EP4214315A1 (es)
JP (1) JP2023542132A (es)
KR (1) KR20230066453A (es)
AU (1) AU2021342503A1 (es)
CA (1) CA3191743A1 (es)
IL (1) IL301197A (es)
MX (1) MX2023003021A (es)
WO (1) WO2022061014A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
JP6454643B2 (ja) * 2012-10-26 2019-01-16 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ 血友病の肝臓指向性遺伝子治療のためのベクター並びにその方法及び使用
PL231230B1 (pl) * 2015-03-11 2019-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Czynnik zwiększający efektywność szczepionki DNA skierowanej przeciw wirusowi, preparat plazmidowy DNA, szczepionka DNA, sposób otrzymywania zmodyfikowanego wektora ekspresyjnego oraz zastosowanie sekwencji nukleotydowej rozpoznawanej przez czynnik NF kappa B
SG11202005281XA (en) * 2017-12-06 2020-07-29 Generation Bio Co Gene editing using a modified closed-ended dna (cedna)

Also Published As

Publication number Publication date
KR20230066453A (ko) 2023-05-15
EP4214315A1 (en) 2023-07-26
WO2022061014A1 (en) 2022-03-24
AU2021342503A1 (en) 2023-04-06
US20230383311A1 (en) 2023-11-30
IL301197A (en) 2023-05-01
JP2023542132A (ja) 2023-10-05
CA3191743A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
AU2017313917B2 (en) CRISPR-Cas genome engineering via a modular AAV delivery system
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
MX2021011037A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos de fenilalanina hidroxilasa (pah).
BR112018008519A2 (pt) construtos específicos de fígado, cassetes de expressão de fator viii e métodos de uso dos mesmos
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
GB0911870D0 (en) Optimised coding sequence and promoter
JP2015529457A5 (es)
EP2637702A1 (en) Methods, compositions, cells, and kits for treating ischemic injury
MX2022011805A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
WO2022198025A3 (en) Non-viral dna vectors and uses thereof for expressing pfic therapeutics
MX2021011039A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
US20240139254A1 (en) Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
Wei et al. Suicide gene therapy against malignant gliomas by the local delivery of genetically engineered umbilical cord mesenchymal stem cells as cellular vehicles
KR20180102025A (ko) C2c1 엔도뉴클레아제를 포함하는 유전체 교정용 조성물 및 이를 이용한 유전체 교정 방법
MX2023003021A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
Ogata et al. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy
WO2020139151A1 (en) Gene therapy dna vector based on gene therapy dna vector vtvaf17
WO2017073689A1 (ja) Ｄｎａ損傷を修復するｒｎａ分子
MX2023003019A (es) Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah).
JP6830651B2 (ja) ペプチド、ポリヌクレオチド、ベクター、形質転換体、ＮＦκＢ阻害剤、及びＮＦκＢ亢進性疾患の治療剤
McCabe et al. β cell cytoprotection using lentiviral vector-based iNOS-specific shRNA delivery
WO2021248408A1 (zh) 一种环状RNA在调控胰岛β细胞增殖中的应用
EA033539B1 (ru) Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани при ее повреждении методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2 в ветеринарии и генетическая конструкция для реализации заявленного способа